$VRNA
Verona Pharma PLC Stock $vrna

$vrna Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000165731224000031 Filed on November 04, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q4
Revenue		$5.624M	$0.00
YoY Change			-100.0%
Cost Of Revenue		$543.0K	$0.00
YoY Change			-100.0%
Gross Profit		$5.081M	$0.00
YoY Change			-100.0%
Gross Profit Margin		90.34%
Selling, General & Admin		$35.20M	$14.97M
YoY Change		163.58%	79.89%
% of Gross Profit		692.7%
Research & Development		$10.55M	$4.122M
YoY Change		256.73%	-39.72%
% of Gross Profit		207.68%
Depreciation & Amortization		$266.0K	$208.0K
YoY Change		71.61%	37.75%
% of Gross Profit		5.24%
Operating Expenses		$46.29M	$19.09M
YoY Change		183.8%	25.94%
Operating Profit		-$40.67M	-$19.09M
YoY Change		149.32%	26.88%
Interest Expense		$9.882M	$3.875M
YoY Change		2364.34%	-16.58%
% of Operating Profit
Other Income/Expense, Net		-$2.045M	$1.034M
YoY Change		-222.6%	29.9%
Pretax Income		-$42.71M	-$14.19M
YoY Change		191.69%	36.09%
Income Tax		$250.0K	-$53.00K
% Of Pretax Income
Net Earnings		-$42.96M	-$14.13M
YoY Change		192.52%	35.22%
Net Earnings / Revenue		-763.9%
Basic Earnings Per Share		-$0.07
Diluted Earnings Per Share		-$0.07	-$0.02
COMMON SHARES
Basic Shares Outstanding	654.6M shares	649.9M shares	639.5M shares
Diluted Shares Outstanding		651.9M shares

Balance Sheet

Concept	2024 Q3	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$336.0M	$271.8M
YoY Change	30.57%	19.29%
Cash & Equivalents	$336.0M	$271.8M
Short-Term Investments
Other Short-Term Assets	$3.443M	$3.365M
YoY Change	-45.51%	-0.68%
Inventory	$4.315M	$0.00
Prepaid Expenses	$7.964M	$3.617M
Receivables	$6.904M	$0.00
Other Receivables	$5.587M
Total Short-Term Assets	$364.3M	$289.7M
YoY Change	31.72%	19.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$40.00K	$24.00K
YoY Change	300.0%	-67.12%
Goodwill	$545.0K	$545.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$15.00M	$15.00M
YoY Change	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$17.57M	$18.42M
YoY Change	10.17%	11.8%
TOTAL ASSETS
Total Short-Term Assets	$364.3M	$289.7M
Total Long-Term Assets	$17.57M	$18.42M
Total Assets	$381.8M	$308.1M
YoY Change	30.55%	18.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.831M	$3.492M
YoY Change	730.01%	20.0%
Accrued Expenses	$18.14M	$3.585M
YoY Change	145.28%	-73.93%
Deferred Revenue	$169.0K	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$27.95M	$8.692M
YoY Change	210.14%	-54.32%
LONG-TERM LIABILITIES
Long-Term Debt	$120.0M	$48.37M
YoY Change	502.91%	395.23%
Other Long-Term Liabilities	$103.4M	$1.775M
YoY Change	516740.0%	765.85%
Total Long-Term Liabilities	$223.4M	$50.15M
YoY Change	1021.09%	402.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.95M	$8.692M
Total Long-Term Liabilities	$223.4M	$50.15M
Total Liabilities	$251.3M	$58.84M
YoY Change	768.53%	102.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$528.5M	-$388.4M
YoY Change	41.27%	16.6%
Common Stock	$42.77M	$42.77M
YoY Change	2.44%	5.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$828.0K	$1.517M
YoY Change	10.99%	-2.07%
Treasury Stock Shares
Shareholders Equity	$130.5M	$249.3M
YoY Change
Total Liabilities & Shareholders Equity	$381.8M	$308.1M
YoY Change	30.55%	18.75%

Cashflow Statement

Concept	2024 Q3	2023 Q4
OPERATING ACTIVITIES
Net Income	-$42.96M	-$14.13M
YoY Change	192.52%	35.22%
Depreciation, Depletion And Amortization	$266.0K	$208.0K
YoY Change	71.61%	37.75%
Cash From Operating Activities	-$62.66M	-$10.40M
YoY Change	392.3%	34.43%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-7.087M	24.01M
YoY Change	-14864.58%	818.59%
NET CHANGE
Cash From Operating Activities	-62.66M	-10.40M
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	-7.087M	24.01M
Net Change In Cash	-69.74M	13.61M
YoY Change	450.06%	-365.61%
FREE CASH FLOW
Cash From Operating Activities	-$62.66M	-$10.40M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$62.66M	-$10.40M
YoY Change	392.3%	34.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1489389
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3 More London Riverside
	dei	Entity Address City Or Town EntityAddressCityOrTown	London
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	SE1 2RE
	dei	Entity Address Country EntityAddressCountry	GB
	dei	Country Region CountryRegion	44
	dei	City Area Code CityAreaCode	203
	dei	Local Phone Number LocalPhoneNumber	283 4200
	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value £0.05 per share*
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	654649358	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	271772000	usd
	dei	Trading Symbol TradingSymbol	VRNA
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	us-gaap	Revenues Revenues	0	usd
	dei	Document Type DocumentType	10-Q
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	336040000	usd
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001657312
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38067
	dei	Entity Registrant Name EntityRegistrantName	Verona Pharma plc
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6904000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7964000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3617000	usd
CY2024Q3	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	5587000	usd
CY2023Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	10954000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	4315000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	3443000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3365000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	364253000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	289708000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	545000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	545000	usd
CY2024Q3	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1980000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2847000	usd
CY2024Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	17565000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	18416000	usd
CY2024Q3	us-gaap	Assets Assets	381818000	usd
CY2023Q4	us-gaap	Assets Assets	308124000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6831000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3492000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18143000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3585000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	169000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	952000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1180000	usd
CY2024Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	1011000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	844000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	435000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	27950000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8692000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	120009000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48374000	usd
CY2024Q3	vrna	Securites Purchased Noncurrent Revenue Interest SecuritesPurchasedNoncurrentRevenueInterest	102019000	usd
CY2023Q4	vrna	Securites Purchased Noncurrent Revenue Interest SecuritesPurchasedNoncurrentRevenueInterest	0	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1349000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1775000	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	223377000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	50149000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	251327000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	667659630	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	667659630	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	654649358	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	643536094	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	42771000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	42771000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	621628000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	601063000	usd
CY2024Q3	us-gaap	Treasury Stock Value TreasuryStockValue	828000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1517000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-388433000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	130491000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	249283000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	381818000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	308124000	usd
CY2024Q3	us-gaap	Revenues Revenues	5624000	usd
CY2023Q3	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	5624000	usd
CY2024Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	543000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8692000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	120009000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48374000	usd
CY2024Q3	vrna	Securites Purchased Noncurrent Revenue Interest SecuritesPurchasedNoncurrentRevenueInterest	102019000	usd
CY2023Q4	vrna	Securites Purchased Noncurrent Revenue Interest SecuritesPurchasedNoncurrentRevenueInterest	0	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1349000	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	223377000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	50149000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	251327000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	58841000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	667659630	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	667659630	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	654649358	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	643536094	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	42771000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	42771000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	621628000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	601063000	usd
CY2024Q3	us-gaap	Treasury Stock Value TreasuryStockValue	828000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1517000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-528479000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-388433000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	130491000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	249283000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	381818000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	308124000	usd
CY2024Q3	us-gaap	Revenues Revenues	5624000	usd
CY2023Q3	us-gaap	Revenues Revenues	0	usd
CY2024Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	543000	usd
CY2023Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	0	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	0	usd
CY2024Q3	vrna	Research And Development Expense Net Of Adjustments ResearchAndDevelopmentExpenseNetOfAdjustments	10552000	usd
CY2023Q3	vrna	Research And Development Expense Net Of Adjustments ResearchAndDevelopmentExpenseNetOfAdjustments	2958000	usd
	vrna	Research And Development Expense Net Of Adjustments ResearchAndDevelopmentExpenseNetOfAdjustments	36704000	usd
	vrna	Research And Development Expense Net Of Adjustments ResearchAndDevelopmentExpenseNetOfAdjustments	13094000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35196000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13353000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	104665000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35381000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	46291000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	16311000	usd
	us-gaap	Operating Expenses OperatingExpenses	141912000	usd
	us-gaap	Operating Expenses OperatingExpenses	48475000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-40667000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16311000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-136288000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-48475000	usd
CY2024Q3	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	1612000	usd
CY2023Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	0	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	543000	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	0	usd
CY2024Q3	vrna	Research And Development Expense Net Of Adjustments ResearchAndDevelopmentExpenseNetOfAdjustments	10552000	usd
CY2023Q3	vrna	Research And Development Expense Net Of Adjustments ResearchAndDevelopmentExpenseNetOfAdjustments	2958000	usd
	vrna	Research And Development Expense Net Of Adjustments ResearchAndDevelopmentExpenseNetOfAdjustments	36704000	usd
	vrna	Research And Development Expense Net Of Adjustments ResearchAndDevelopmentExpenseNetOfAdjustments	13094000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35196000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13353000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	104665000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35381000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	46291000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	16311000	usd
	us-gaap	Operating Expenses OperatingExpenses	141912000	usd
	us-gaap	Operating Expenses OperatingExpenses	48475000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-40667000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16311000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-136288000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-48475000	usd
CY2024Q3	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	1612000	usd
CY2023Q3	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	-309000	usd
	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	3044000	usd
	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	70000	usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3653000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2024Q3	us-gaap	Investment Income Net InvestmentIncomeNet	4750000	usd
CY2023Q3	us-gaap	Investment Income Net InvestmentIncomeNet	3390000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	11268000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	9469000	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	9882000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	401000	usd
	us-gaap	Interest Expense InterestExpense	13225000	usd
	us-gaap	Interest Expense InterestExpense	1434000	usd
CY2024Q3	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	1475000	usd
CY2023Q3	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	-1012000	usd
	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	1281000	usd
	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	660000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2045000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1668000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1285000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8765000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42712000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14643000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-137573000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39710000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	250000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2018000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	527000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-42962000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-14687000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-139591000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-40237000	usd
CY2023Q3	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	-309000	usd
	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	3044000	usd
	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	70000	usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3653000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2024Q3	us-gaap	Investment Income Net InvestmentIncomeNet	4750000	usd
CY2023Q3	us-gaap	Investment Income Net InvestmentIncomeNet	3390000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	11268000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	9469000	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	9882000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	401000	usd
	us-gaap	Interest Expense InterestExpense	13225000	usd
	us-gaap	Interest Expense InterestExpense	1434000	usd
CY2024Q3	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	1475000	usd
CY2023Q3	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	-1012000	usd
	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	660000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2045000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1668000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1285000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8765000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42712000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14643000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-137573000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39710000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	250000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2018000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	527000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-42962000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-139591000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	651944000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	651944000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	638239000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	638239000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	638239000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	638239000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	648633000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	648633000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	631448000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	631448000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	631448000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	631448000	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	249283000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-25794000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	816000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	651944000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	651944000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	638239000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	638239000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	638239000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	638239000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	648633000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	648633000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	631448000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	631448000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	631448000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	631448000	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	249283000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-25794000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	816000	usd
CY2024Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3338000	usd
CY2024Q1	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	237000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4258000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	224988000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	168274000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-42962000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3668000	usd
CY2024Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	5600000	usd
CY2024Q3	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	543000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7654000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	130491000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	230466000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16743000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1827000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4290000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	276749000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8807000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	77000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	273093000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-14687000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	48000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5079000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	263533000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-139591000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-40237000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1281000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	660000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	777000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	103000	usd
	us-gaap	Accretion Expense AccretionExpense	5511000	usd
	us-gaap	Accretion Expense AccretionExpense	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	120000	usd
CY2024Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3338000	usd
CY2024Q1	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	237000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4258000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	224988000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	168274000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-42962000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3668000	usd
CY2024Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	5600000	usd
CY2024Q3	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	543000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7654000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	130491000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	230466000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16743000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1827000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4290000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	276749000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8807000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	77000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5074000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	273093000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-14687000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	48000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5079000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	263533000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-139591000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-40237000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1281000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	660000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	777000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	103000	usd
	us-gaap	Accretion Expense AccretionExpense	5511000	usd
	us-gaap	Accretion Expense AccretionExpense	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	120000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	84000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3653000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	27506000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	14443000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	799000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	469000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6904000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	4347000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	833000	usd
	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	-5590000	usd
	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	70000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4315000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	832000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2260000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3435000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2087000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	14742000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6355000	usd
	vrna	Increase Decrease In License Agreement Obligations IncreaseDecreaseInLicenseAgreementObligations	169000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	84000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	27506000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	14443000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	799000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	469000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6904000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	4347000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	833000	usd
	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	-5590000	usd
	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	70000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4315000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	832000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2260000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3435000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2087000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	14742000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6355000	usd
	vrna	Increase Decrease In License Agreement Obligations IncreaseDecreaseInLicenseAgreementObligations	169000	usd
	vrna	Increase Decrease In License Agreement Obligations IncreaseDecreaseInLicenseAgreementObligations	0	usd
	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-573000	usd
	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-484000	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	1765000	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-954000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	409000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-979000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-93367000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39820000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-45000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56909000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	122500000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9996000	usd
	vrna	Proceeds From Revenue Interest Purchase And Sale Agreement Ripsa ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA	100000000	usd
	vrna	Proceeds From Revenue Interest Purchase And Sale Agreement Ripsa ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	6915000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	52256000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	11191000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4484000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1952000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	156622000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	68857000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1058000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	502000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	64268000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29539000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	271772000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	227827000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	336040000	usd
	vrna	Increase Decrease In License Agreement Obligations IncreaseDecreaseInLicenseAgreementObligations	0	usd
	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-573000	usd
	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-484000	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	1765000	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-954000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	409000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-979000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-93367000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39820000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-45000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56909000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	122500000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9996000	usd
	vrna	Proceeds From Revenue Interest Purchase And Sale Agreement Ripsa ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA	100000000	usd
	vrna	Proceeds From Revenue Interest Purchase And Sale Agreement Ripsa ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	6915000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	52256000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	11191000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4484000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1952000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	156622000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	68857000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1058000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	502000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	64268000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29539000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	271772000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	227827000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	336040000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	257366000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	249000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1215000	usd
	us-gaap	Interest Paid Net InterestPaidNet	6452000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1228000	usd
	vrna	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1	subsidiary
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-528500000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	257366000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	249000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1215000	usd
	us-gaap	Interest Paid Net InterestPaidNet	6452000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1228000	usd
	vrna	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1	subsidiary
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-528500000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, gross-to-net revenue adjustments, amortization and carrying value of the revenue interest purchase and sale agreement (“RIPSA”), and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known, and actual results could differ from the Company’s estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Inventory, including Pre-Launch Inventory</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company values its inventories at the lower of actual cost or net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis. When the Company expects to utilize the inventory beyond one year we record it in inventories, long-term on its consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prior to obtaining initial regulatory approval for Ohtuvayre, the Company expensed costs relating to production of pre-launch inventory as research and development (“R&D”) expense in its consolidated statements of operations and comprehensive loss in the period incurred. Inventory acquired and the related costs after June 26, 2024, the date of the FDA’s approval of Ohtuvayre, are capitalized. Products used in clinical trials are expensed as research and development expense in the statement of operations and comprehensive loss. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess or obsolete inventory to its net realizable value in the period in which the impairment is identified through cost of product and other revenue in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, the Company’s product is subject to strict quality control and monitoring that is performed throughout the manufacturing process, including release of work-in-process to finished goods. In the event that certain batches or units of product do not meet quality specifications, the Company will record a write-down of any potential unmarketable inventory to its estimated net realizable value and record the expense as cost of sales in the consolidated statements of operations and comprehensive loss. No inventory was written down as a result of excess, obsolescence, scrap, or other reasons during the three or nine months ended September 30, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.241%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,315 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Revenue Interest Purchase and Sale Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The RIPSA is eligible to be repaid based on royalties from net sales of Ohtuvayre (ensifentrine) and any other future products. Interest expense is calculated using the effective interest method over the estimated period the related liability will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of the RIPSA and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of the liability, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company’s revenues consist of product sales of Ohtuvayre. The Company accounts for contracts with its customers in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Pursuant to ASC 606, for arrangements or transactions between participants determined to be within the scope of the contracts with customers guidance, the Company performs the following five steps to determine the appropriate amount of revenue to be recognized as the Company fulfills its obligations: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Product Sales, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company’s revenue from net product sales was generated in the United States following the FDA’s approval for marketing of Ohtuvayre for the treatment of COPD in June 2024. The Company sells Ohtuvayre principally through arrangements with specialty pharmacies (“SPs”), who are the Company’s customers. The customers subsequently resell the product to patients and health care providers. The Company applies the ASC 606 five step process discussed above to the contracts with SPs. The Company provides limited right of return to the customers in cases of shipment errors or expiring or defective products. Product revenues are recognized when the customers take control of the product, which occurs upon delivery to the customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company recognizes revenue from product sales at the net sales price which includes estimates of variable consideration for which reserves are established and reflects each of these as a reduction to revenue. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which the Company is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">results in the future vary from estimates, the Company may need to adjust its estimates, which would affect net revenue in the period of adjustment. The following are the Company’s significant categories of variable consideration:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Distribution Fees: The Company pays distribution fees to SPs in connection with the sales of its product. These distributor fees are based on a contractually determined fixed percentage of sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Government rebates and chargebacks: The Company contracts with Medicaid, Medicare, and other government agencies (“Government Payors”) so that Ohtuvayre will be eligible for purchase by, or partial or full reimbursement from, such Government Payors. The Company estimates the rebates, chargebacks and discounts it will provide to Government Payors and deducts these estimated amounts from its gross product revenue at the time the revenue is recognized. The Company estimates these reserves based upon its contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix, resulting in a reduction of product revenue and the establishment of a current liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Commercial Chargebacks: Chargebacks are discounts and fees related to contracts with various third-party payers and programs that purchase from SPs at a discounted price. SPs charge back to the Company the difference between the price initially paid by SPs and the discounted price paid to SPs by these entities. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Product Returns: Consistent with industry practice, the Company offers SPs limited product return rights for shipment errors or expiring or defective products. The Company makes a reasonable estimate of future potential product returns based on inventory reports from SPs, visibility into the inventory distribution channel, the underlying product demand, and industry data specific to the specialty pharmaceutical distribution industry. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Co-pay assistance: Other incentives which the Company offers include voluntary patient assistance and assurance programs, such as a co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other fees: Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">License Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company’s revenue may also at times consist of revenue from the Company’s strategic agreements for the development and commercialization of ensifentrine. The terms of the agreements may include non-refundable upfront fees, payments based upon achievement of milestones and eventually revenue from the commercialized product. These agreements usually have both fixed and variable consideration. Non-refundable upfront fees are considered fixed, while milestone payments and revenue from the commercialized product are identified as variable consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. If the right to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the right when the right is transferred to the customer, and the customer can use and benefit from the right.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the inception of the arrangement, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable of being achieved until those approvals are received. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently issued accounting standards not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The amendments in this ASU are effective for annual periods beginning on December 15, 2024, and should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its income tax disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity's overall performance and assess potential future cash flows. The amendments in this ASU are effective for annual periods beginning on December 15, 2023 and interim periods beginning on December 15, 2024 and should be applied on a retrospective basis for all periods presented. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its segment disclosures.</span></div>
CY2024Q3	us-gaap	Inventory Net InventoryNet	4315000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	4315000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, gross-to-net revenue adjustments, amortization and carrying value of the revenue interest purchase and sale agreement (“RIPSA”), and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known, and actual results could differ from the Company’s estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Inventory, including Pre-Launch Inventory</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company values its inventories at the lower of actual cost or net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis. When the Company expects to utilize the inventory beyond one year we record it in inventories, long-term on its consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prior to obtaining initial regulatory approval for Ohtuvayre, the Company expensed costs relating to production of pre-launch inventory as research and development (“R&D”) expense in its consolidated statements of operations and comprehensive loss in the period incurred. Inventory acquired and the related costs after June 26, 2024, the date of the FDA’s approval of Ohtuvayre, are capitalized. Products used in clinical trials are expensed as research and development expense in the statement of operations and comprehensive loss. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess or obsolete inventory to its net realizable value in the period in which the impairment is identified through cost of product and other revenue in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, the Company’s product is subject to strict quality control and monitoring that is performed throughout the manufacturing process, including release of work-in-process to finished goods. In the event that certain batches or units of product do not meet quality specifications, the Company will record a write-down of any potential unmarketable inventory to its estimated net realizable value and record the expense as cost of sales in the consolidated statements of operations and comprehensive loss. No inventory was written down as a result of excess, obsolescence, scrap, or other reasons during the three or nine months ended September 30, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.241%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,315 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Revenue Interest Purchase and Sale Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The RIPSA is eligible to be repaid based on royalties from net sales of Ohtuvayre (ensifentrine) and any other future products. Interest expense is calculated using the effective interest method over the estimated period the related liability will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of the RIPSA and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of the liability, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company’s revenues consist of product sales of Ohtuvayre. The Company accounts for contracts with its customers in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Pursuant to ASC 606, for arrangements or transactions between participants determined to be within the scope of the contracts with customers guidance, the Company performs the following five steps to determine the appropriate amount of revenue to be recognized as the Company fulfills its obligations: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Product Sales, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company’s revenue from net product sales was generated in the United States following the FDA’s approval for marketing of Ohtuvayre for the treatment of COPD in June 2024. The Company sells Ohtuvayre principally through arrangements with specialty pharmacies (“SPs”), who are the Company’s customers. The customers subsequently resell the product to patients and health care providers. The Company applies the ASC 606 five step process discussed above to the contracts with SPs. The Company provides limited right of return to the customers in cases of shipment errors or expiring or defective products. Product revenues are recognized when the customers take control of the product, which occurs upon delivery to the customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company recognizes revenue from product sales at the net sales price which includes estimates of variable consideration for which reserves are established and reflects each of these as a reduction to revenue. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which the Company is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">results in the future vary from estimates, the Company may need to adjust its estimates, which would affect net revenue in the period of adjustment. The following are the Company’s significant categories of variable consideration:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Distribution Fees: The Company pays distribution fees to SPs in connection with the sales of its product. These distributor fees are based on a contractually determined fixed percentage of sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Government rebates and chargebacks: The Company contracts with Medicaid, Medicare, and other government agencies (“Government Payors”) so that Ohtuvayre will be eligible for purchase by, or partial or full reimbursement from, such Government Payors. The Company estimates the rebates, chargebacks and discounts it will provide to Government Payors and deducts these estimated amounts from its gross product revenue at the time the revenue is recognized. The Company estimates these reserves based upon its contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix, resulting in a reduction of product revenue and the establishment of a current liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Commercial Chargebacks: Chargebacks are discounts and fees related to contracts with various third-party payers and programs that purchase from SPs at a discounted price. SPs charge back to the Company the difference between the price initially paid by SPs and the discounted price paid to SPs by these entities. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Product Returns: Consistent with industry practice, the Company offers SPs limited product return rights for shipment errors or expiring or defective products. The Company makes a reasonable estimate of future potential product returns based on inventory reports from SPs, visibility into the inventory distribution channel, the underlying product demand, and industry data specific to the specialty pharmaceutical distribution industry. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Co-pay assistance: Other incentives which the Company offers include voluntary patient assistance and assurance programs, such as a co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other fees: Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">License Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company’s revenue may also at times consist of revenue from the Company’s strategic agreements for the development and commercialization of ensifentrine. The terms of the agreements may include non-refundable upfront fees, payments based upon achievement of milestones and eventually revenue from the commercialized product. These agreements usually have both fixed and variable consideration. Non-refundable upfront fees are considered fixed, while milestone payments and revenue from the commercialized product are identified as variable consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. If the right to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the right when the right is transferred to the customer, and the customer can use and benefit from the right.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the inception of the arrangement, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable of being achieved until those approvals are received. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently issued accounting standards not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The amendments in this ASU are effective for annual periods beginning on December 15, 2024, and should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its income tax disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity's overall performance and assess potential future cash flows. The amendments in this ASU are effective for annual periods beginning on December 15, 2023 and interim periods beginning on December 15, 2024 and should be applied on a retrospective basis for all periods presented. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its segment disclosures.</span></div>
CY2024Q3	us-gaap	Inventory Net InventoryNet	4315000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	4315000	usd
CY2024Q3	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	6414000	usd
CY2023Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	752000	usd
CY2024Q3	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	4463000	usd
CY2023Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	2039000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7266000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	794000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18143000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3585000	usd
CY2024Q3	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	6414000	usd
CY2023Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	752000	usd
CY2024Q3	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	4463000	usd
CY2023Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	2039000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7266000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	794000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18143000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3585000	usd
CY2024Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.25
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7654000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5079000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27506000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14443000	usd
CY2024Q3	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24689624	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2432000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	64000	shares
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1037424	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	26020200	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7924000	shares
CY2024Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.25
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7654000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14443000	usd
CY2024Q3	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24689624	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2432000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	64000	shares
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1037424	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	26020200	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7924000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	72000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	160000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	33712200	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2056000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	107632	shares
CY2024Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2654960	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	33005608	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	72000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	160000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	33712200	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2056000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	107632	shares
CY2024Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2654960	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	33005608	shares
CY2024Q3	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-42962000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-14687000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-139591000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-40237000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	651944000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	651944000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	638239000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	638239000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	638239000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	638239000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	648633000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	648633000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	631448000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	631448000	shares
CY2024Q3	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-42962000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-14687000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-139591000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-40237000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	651944000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	651944000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	638239000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	638239000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	638239000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	638239000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	648633000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	648633000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	631448000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	631448000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	631448000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	631448000	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50200000	shares
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50200000	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	45900000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	45900000	shares
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	631448000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	631448000	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50200000	shares
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50200000	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	45900000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	45900000	shares
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001657312-24-000031-index-headers.html	Edgar Link	pending
0001657312-24-000031-index.html	Edgar Link	pending
0001657312-24-000031.txt	Edgar Link	pending
0001657312-24-000031-xbrl.zip	Edgar Link	pending
exhibit311q324.htm	Edgar Link	pending
exhibit312q324.htm	Edgar Link	pending
exhibit321q324.htm	Edgar Link	pending
exhibit322q324.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrna-20240930.htm	Edgar Link	pending
vrna-20240930.xsd	Edgar Link	pending
vrna-20240930_g1.jpg	Edgar Link	pending
vrna-20240930_cal.xml	Edgar Link	unprocessable
vrna-20240930_def.xml	Edgar Link	unprocessable
vrna-20240930_lab.xml	Edgar Link	unprocessable
vrna-20240930_pre.xml	Edgar Link	unprocessable
vrna-20240930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRNA
Verona Pharma PLC Stock $vrna

2024 Q4 Form 10-Q Financial Statement

#000165731224000031 Filed on November 04, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA Verona Pharma PLC Stock $vrna

2024 Q4 Form 10-Q Financial Statement

#000165731224000031 Filed on November 04, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA
Verona Pharma PLC Stock $vrna